Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188520 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
A Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 564
- Enrollment target
- 14
- Study locations
NCT06188520: Recruiting Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), sponsored by AstraZeneca.
NCT06188520 is a Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 564 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (840% higher). The trial reports 14 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06188520, a Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 564 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
Primary Outcome
Percentage of participants with incidence of DLTs.
Conditions Studied
Interventions
- DRUG Camizestrant
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG AZD8421
Study Locations (14)
Other
- Research Site - East Melbourne
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Pamplona
- Research Site - Valencia
- Research Site - Cambridge
- Research Site - Leeds
- Research Site - London
- Research Site - Manchester
Missouri
- Research Site - St Louis
Rhode Island
- Research Site - Providence
Tennessee
- Research Site - Nashville
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2027-08-04 |
| Phase | Phase 1 |
What NCT06188520 shows while recruiting
NCT06188520 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (840% higher).
The record links to 2 conditions, with ER+ HER2- Advanced Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Camizestrant is the first listed.
NCT06188520 lists 14 locations in 5 states (Other, Missouri, Rhode Island).
Frequently Asked Questions
What is clinical trial NCT06188520 about?
NCT06188520 is a clinical study titled "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors". This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
What is the current status of trial NCT06188520?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 564 participants. The study started on 2023-12-05. Estimated completion is 2027-08-04.
What conditions does trial NCT06188520 study?
This clinical trial studies the following conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC).
What interventions are being tested in trial NCT06188520?
The interventions under investigation include: Camizestrant (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), AZD8421 (DRUG).
Who is sponsoring clinical trial NCT06188520?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188520 being conducted?
This trial has 14 study locations across Missouri, Rhode Island, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ER+ HER2- Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06188520's enrollment target sits among peer trials
564 35th of 2000 higher than 1,966 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
- NCT07007065 · 561 participants · Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI